Evidence map›Paper›PMID 25592620›Full record

ArticleJournal of the American Academy of Dermatology2015

Histologic features of melanoma associated with CDKN2A genotype.

Michael R Sargen, Peter A Kanetsky, Julia Newton-Bishop, Nicholas K Hayward, Graham J Mann, Nelleke A Gruis, Margaret A Tucker, Alisa M Goldstein, Giovanna Bianchi-Scarra, Susana Puig and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American Academy of Dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Unraveling the Wide Spectrum of Melanoma Biomarkers.Diagnostics (Basel, Switzerland) · 2021
    Review
  6. Article
  7. Germline mutations predisposing to melanoma.Journal of cutaneous pathology · 2020
    Review
  8. Current Molecular Markers of Melanoma and Treatment Targets.International journal of molecular sciences · 2020
    Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 6 countries.

Michael R SargenDepartment of Dermatology, Emory University Hospital, Atlanta, Georgia. Electronic address: michael.sargen@emory.edu.
Peter A KanetskyDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Julia Newton-BishopSection of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, Leeds, United Kingdom.
Nicholas K HaywardQueensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute, Brisbane, Australia.
Graham J MannUniversity of Sydney at Westmead Millennium Institute and Melanoma Institute Australia, Sydney, Australia.
Nelleke A GruisDepartment of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
Margaret A TuckerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Alisa M GoldsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Giovanna Bianchi-ScarraDepartment of Internal Medicine and Medical Specialties (Di.M.I.) University of Genoa, Genetics of Rare Cancers, Istituto Di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria (IRCCS AOU) San Martino -IST, Genoa, Italy.
Susana PuigHospital Clinic of Barcelona, University of Barcelona, Institut de Recerca Biomédica August Pi I Sunyer, Barcelona, Spain; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain.
David E ElderDepartment of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Division of Cancer Epidemiology and GeneticsEmory University Hospital · USHospital of the University of Pennsylvania · USInstituto de Investigación de Enfermedades Raras · ESLeiden University Medical Center · NLMoffitt Cancer Center · USQIMR Berghofer Medical Research Institute · AUUniversity of Genoa · ITUniversity of Leeds · GBUniversity of Sydney · AU

Funding

Genetic Epidermiology of MelanomaR01CA083115 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BISHOP, DAVID TIMOTHY, ELDER, DAVID ERIC · 2001 to 2017
$13.0M
Integrative Molecular Epidemiology WorkshopR25CA174664 · NCI · AMERICAN ASSOCIATION FOR CANCER RESEARCH · PI Shelley S Tworoger · 2013 to 2026
$2.8M
Cancer Research UK 19167NCI NIH HHS R01 CA083115NCI NIH HHS R01 CA83115NCI NIH HHS R25 CA174664
6 · The paper itself

Abstract

backgroundInherited susceptibility genes have been associated with histopathologic characteristics of tumors.

objectiveWe sought to identify associations between histology of melanomas and CDKN2A genotype.

methodsThis was a case-control study design comparing 28 histopathologic tumor features among individuals with sporadic melanomas (N = 81) and cases from melanoma families with (N = 123) and without (N = 120) CDKN2A germline mutations.

resultsCompared with CDKN2A(-) cases, mutation carriers tended to have histologic features of superficial spreading melanoma subtype including higher pigmentation (Ptrend = .02) and increased pagetoid scatter (Ptrend = .07) after adjusting for age at diagnosis, sex, and American Joint Committee on Cancer thickness category. Similar associations were observed when comparing mutation carriers with a combined group of CDKN2A(-) (wild type) and sporadic melanomas. The presence of spindle cell morphology in the vertical growth phase was also an important predictor of genotype. Of the 15 cases with this phenotype, none were observed to harbor a CDKN2A mutation. LIMITATIONS: Our study examined rare mutations and may have been underpowered to detect small, but biologically significant associations between histology and genotype.

conclusionFamilial melanomas with CDKN2A mutations preferentially express a histologic phenotype of dense pigmentation, high pagetoid scatter, and a non-spindle cell morphology in the vertical growth phase.

Indexed as

MutationAdultCase-Control StudiesCyclin-Dependent Kinase Inhibitor p16FemaleGenotypeHumansMaleMelanomaMiddle AgedSkin NeoplasmsCyclin-Dependent Kinase Inhibitor p16CDKN2Aclassification and regression tree analysisfamilial melanomagenetic testinghistologypagetoid scatterpigmentationsporadic melanoma

Identifiers

PMID25592620
PMCPMC4333073
OpenAlexW2120603559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.